Chimerix (CMRX)
(Delayed Data from NSDQ)
$0.95 USD
0.00 (0.28%)
Updated May 3, 2024 04:00 PM ET
After-Market: $0.95 0.00 (-0.30%) 7:58 PM ET
4-Sell of 5 4
C Value F Growth D Momentum F VGM
Chimerix (CMRX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$7.33 | $11.00 | $5.00 | 671.58% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for Chimerix comes to $7.33. The forecasts range from a low of $5.00 to a high of $11.00. The average price target represents an increase of 671.58% from the last closing price of $0.95.
Analyst Price Targets (6 )
Broker Rating
Chimerix currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by six brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on six recommendations.
Of the six recommendations deriving the current ABR, six are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 6 | 6 | 6 | 6 | 6 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/1/2024 | Capital One Securities | Naureen Quibria | Strong Buy | Strong Buy |
4/1/2024 | Robert W. Baird & Co. | Joel L Beatty | Strong Buy | Strong Buy |
3/1/2024 | H.C. Wainwright & Co. | Edward White | Strong Buy | Strong Buy |
2/12/2024 | Wedbush Securities | David M Nierengarten | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 6 |
Average Target Price | $7.33 |
LT Growth Rate | NA |
Industry | Medical - Products |
Industry Rank by ABR | 151 of 252 |
Current Quarter EPS Est: | -0.22 |